Background. Aerococcus urinae is an emerging urinary pathogen frequently identified by MALDI-TOF. It is generally susceptible to β-lactams, however, its susceptibility pattern to fluoroquinolones (FQ) remains variable. The goals of this study were (i) to evaluate the performance of the gradient diffusion method (Etest ® ) to determine FQ resistance compared with broth microdilution (BMD) and (ii) to estimate the resistance rate of A. urinae toward FQ in Quebec hospitals.
Background. Ventilator-associated pneumonia (VAP) is one of the most commonly encountered hospital-acquired infections worldwide, and one of the major contributors to an over mortality in critically ill patients. Initial empirical antimicrobial therapy is often broad-spectrum. Fast identification and quantification of microorganisms is of great importance to enable early effective targeted antimicrobial treatment. This trial compares the performance of the new BioFire ® Pneumonia Panel (BPP) with quantitative conventional culture (CC) and an independent real-time quantitative molecular-based method (MM), in Intensive Care Unit (ICU) patients with VAP suspicion.
Methods. Bronchoalveolar lavage (BAL) specimens from 120 patients with suspected VAP, enrolled at four different French ICUs, during January to November 2013, were analysed by CC, following microbiological standard procedures, by BPP and MM. A total of 15 bacterial targets, commonly detected by the three methods, were analysed for concordance above an agreed threshold for positivity. While every step is fully integrated, from specimen-to-results (BPP), bacterial DNA was extracted from each sample on the NucliSENS easyMAG® Platform, and real-time polymerase chain reactions were run in an ABI 7500 Dx thermocycler (MM).
Results. A total of 117 different BAL specimens were processed. Positive culture was obtained for 65.8% of BAL, while positive detections were observed in 79.4% with BPP and 75.4% with independent MM. Fourteen different species were detected by the three methods, with majority of the bacteria being S. Background. There are limited data on routine use of anaerobic blood cultures and the prevalence of patients with anaerobic bacteremia in Thailand.
Methods. Thammasat University Hospital is a 650-bed university hospital located in central Thailand. We implemented routine blood culture work up for adults using paired aerobic/anaerobic bottles using the BACTEC FX system (BD Diagnostics) as a standard practice. Gram stain and inoculation of positive blood cultures on aerobic and anaerobic culture media were performed and maintained in anaerobic conditions by the Anoxomat™ system (Mart Microbiology). Vitek2 system (BioMerieux) was used for bacterial identification. Data on positive blood cultures, bacterial identification, and time to positivity (TTP) between aerobic and anaerobic bottles were compared. Characteristics of patients with bacteremia were reviewed.
Results. During December 2016-October 2017, 323 blood culture sets were processed (one BACTEC anaerobic Plus bottle and two aerobic bottles). Majority of samples received were from patients hospitalized in an intensive care unit (surgical ICU 28% and medical ICU 25%) followed by general medical unit (19%) and surgical unit (16%). There were 21 positive cultures from anaerobic bottles (21/323, 6.5%) vs. 30 positive cultures from aerobic bottle (30/646, 4.6%) (P = 0.3). Bacteria isolated from anaerobic bottles included Staphylococcus aureus (n = 8), coagulase-negative staphylococci (n = 3), viridans group streptococci (n = 1), Klebsiella pneumoniae (n = 8), and Escherichia coli (n = 1). Positivity rate of Gram-positive bacteria (GP) from anaerobic bottle was slightly higher than the rate of GP from aerobic bottle (12/203, 3.1% vs. 12/646, 1.9%; P = 0.08) There was no isolation of anaerobic bacteria. TTP from anaerobic bottles (mean of 15.6 hours, range 11-26 hours) was significantly faster than TTP from aerobic bottles (mean of 49.5 hours, range 13-100 hours) (P <0.001). The majority of the positive samples were from patients hospitalized in an ICU (16/21, 76.2%), especially in a surgical ICU (13/21, 61.9%).
Conclusion. Our population had a low prevalence of anaerobic bacteremia. The anaerobic bottle significantly decreased the TTP compared with an aerobic bottle. The cost-effectiveness of routinely including an anaerobic blood culture bottle needs further study.
Disclosures. Background. Staphylococcus aureus (SA) is a major human pathogen, causing a variety of nosocomial and community-acquired infections. Nasal carriers of SA are at increased risk for healthcare associated infections with this organism. Timely detection of SA and Methicillin-resistant Staphylococcus aureus (MRSA) and decolonization of pre-surgical patients carrying SA are of importance in infection prevention. We sought to evaluate the clinical performance of the Xpert SA Nasal Complete assay (Xpert SA) for detection of SA and MRSA in the nasal specimens from pediatric patients.
Methods. A total of 504 nasal specimens were collected in the Copan dual swab systems from patients with ages between 0 to 61 years with 91.9% patients ≤21 yearold (n = 463). For each sample, one swab was tested with Xpert SA. The second swab was plated onto Blood agar, Mannitol salt agar and ChromID™ MRSA plate and incubated at 35°C in non-CO 2 incubator. The identification of SA and MRSA was compared between Xpert SA and the culture results. Methicillin resistance was determined using conventional methods (susceptibility testing or detection of altered penicillin binding protein).
Results. When compared with culture for the identification of SA (n = 481), there was an agreement of 95.0% with sensitivity and specificity being 95.6% and 94.8%, respectively. Among those culture-confirmed and Xpert SA positive samples (n = 131), concordance between Xpert SA and conventional methods for detection of methicillin resistance was 97.0% with sensitivity and specificity being 100% and 96.3%, respectively. Four culture-confirmed methicillin-susceptible SA (MSSA) were identified as MRSA by Xpert SA. Among 504 nasal specimens, 23 (4.6%) samples had invalid or instrument failure results. Nasal swabs collected from pediatric patients (≤21-year-old) had a higher invalid/instrument failure rate (5.0%) than those from adults (0%) (P < 0.001).
Conclusion. Xpert SA Nasal Complete assay provides a rapid and sensitive method to detect and differentiate between MSSA and MRSA colonization. The higher invalid rate in pediatric patients and misidentification of MSSA as MRSA by Xpert SA warrant the confirmation by bacterial culture and conventional susceptibility test.
Disclosures. A. Leber, Nationwide Children's Hospital: Research Contractor, Research support. Results. A total of 140 HCP underwent initial T-SPOT; the median age was 27 years (IQR 25-31 years), 89% were female and 23 (16%) were T-SPOT-positive. Eighty-nine HCP (64%) had both initial and follow-up T-SPOTs. Among the 89 HCP, the initial and follow-up rates of T-SPOT positivity were 19% (N = 17) and 24% (N = 21), respectively. The conversion and reversion rates were 10% (N = 9) and 6% (N = 5), respectively. All of the nine HCP (100%) with T-SPOT conversion reported significant contacts with patients who had active pulmonary TB without using appropriate personal protection equipment. During the 1-year follow-up period, incidence of TB were significantly higher among HCP with T-SPOT conversion compared with HCP with persistent positive T-SPOT, HCP with T-SPOT reversion and HCP with persistent negative T-SPOT [22 vs. 8 vs. 0 vs. 0 cases/100 person-years; P < 0.001]. Of the 17 HCP with positive initial T-SPOT, 8 (47%) completed IPT. The incidence of TB was significantly lower and the T-SPOT reversion rate was significantly higher among HCP completing IPT compared with HCP declining or not completing IPT (0 vs. 11 cases/100 person-years; P < 0.001 and 63% vs. 0%; P = 0.009, respectively).
T-SPOT
Conclusion. T-SPOT could be used for diagnosing LTBI, guiding IPT and identifying HCP with subsequent risk for TB. The serial T-SPOT may be used for evaluating IPT efficacy.
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